Novo Nordisk ADR (NVO) concluded trading on Wednesday at a closing price of $123.29, with 5.67 million shares of worth about $698.96 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 33.21% during that period and on Wednesday the price saw a gain of about 2.75%. Currently the company’s common shares owned by public are about 3.38B shares, out of which, 3.38B shares are available for trading.
However, the stock later moved at a day high price of 123.34, or with a gain of 2.75%. Stock saw a price change of 3.90% in past 5 days and over the past one month there was a price change of 15.93%. Year-to-date (YTD), NVO shares are showing a performance of 19.18% which increased to 72.45% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $67.66 but also hit the highest price of $121.65 during that period. The average intraday trading volume for Novo Nordisk ADR shares is 4.42 million. The stock is currently trading 9.69% above its 20-day simple moving average (SMA20), while that difference is up 16.13% for SMA50 and it goes to 32.07% higher than SMA200.
Novo Nordisk ADR (NYSE: NVO) currently have 3.38B outstanding shares and institutions hold larger chunk of about 9.10% of that.
The stock has a current market capitalization of $417.14B and its 3Y-monthly beta is at 0.41. PE ratio of stock for trailing 12 months is 45.64, while it has posted earnings per share of $2.70 in the same period. Its PEG reads 16.30 and has Quick Ratio of 0.64 while making debt-to-equity ratio of 0.25. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NVO, volatility over the week remained 1.49% while standing at 1.64% over the month.
Analysts are in expectations that Novo Nordisk ADR (NVO) stock would likely to be making an EPS of $NIO Inc. in the current quarter, while forecast for next quarter EPS is $6.00 and it is $Stocks for next year. For the current quarter EPS, analysts have given the company a lowest target $Novo Nordisk A/S which is $Vornado Realty Trust at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $Novartis AG in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 23.47% while it is estimated to increase by 20.10% in next year. EPS is likely to shrink at an annualized rate of 2.80% for next 5-years, compared to annual growth of 16.48% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Morgan Stanley on January 23, 2024 offering an Overweight rating for the stock and assigned a target price of $120 to it.
